Musculoskeletal · Metabolic Bone Disease
The facts most likely to be tested
Paget disease of bone is characterized by disordered osteoclast-mediated bone resorption followed by disorganized, excessive bone formation.
Patients are frequently asymptomatic and diagnosed incidentally by an isolated elevation in serum alkaline phosphatase (ALP) with normal calcium and phosphate levels.
The classic radiographic appearance is a lytic-sclerotic lesion often described as cortical thickening and bone expansion.
Common clinical manifestations include bone pain, headache, hearing loss due to cranial nerve impingement, and increased hat size.
The most feared and serious complication of Paget disease is the development of osteosarcoma, which should be suspected if there is a sudden increase in pain or a new soft tissue mass.
Bisphosphonates are the first-line pharmacologic treatment used to suppress osteoclast activity and normalize bone turnover.
Advanced disease may lead to high-output heart failure due to the development of hypervascularity and arteriovenous shunts within the affected bone.
Vignette unlocked
A 68-year-old male presents for a routine physical exam. He reports no specific complaints, but his wife notes that he has had to purchase larger hats over the past year and has complained of mild, dull aching in his right tibia. Physical exam reveals bony enlargement of the right tibia and decreased auditory acuity on the right side. Laboratory studies show an isolated elevation in alkaline phosphatase with normal serum calcium, phosphorus, and parathyroid hormone levels. Radiographs of the tibia demonstrate cortical thickening and coarsened trabeculae.
What is the most appropriate first-line pharmacologic treatment for this patient?
Bisphosphonates
The patient presents with classic signs of Paget disease of bone (increased hat size, hearing loss, elevated ALP). Bisphosphonates are the treatment of choice to inhibit osteoclast activity and prevent further bone remodeling.
Full handout
High yield triage
Etiology / Epidemiology
Common in older adults >55; higher prevalence in European descent.
Clinical Manifestations
Often asymptomatic; bone pain and chalk-stick fractures are classic.
Diagnosis
Elevated alkaline phosphatase; plain radiographs show lytic/sclerotic lesions.
Treatment
Bisphosphonates are first-line; esophagitis is a major side effect.
Prognosis
Risk of osteosarcoma; monitor with serial alkaline phosphatase levels.
Full handout
Epidemiology & Etiology
Primarily affects patients >55 years old with a strong predilection for those of British/European ancestry. It is rare in individuals under 40. The etiology is likely a combination of genetic predisposition and a paramyxovirus infection triggering abnormal bone remodeling.
Pertinent Anatomy
Commonly involves the axial skeleton, specifically the pelvis, lumbar spine, skull, and femur. Involvement of the skull can lead to cranial nerve entrapment due to bony overgrowth.
Pathophysiology
Characterized by a three-phase cycle: initial osteoclastic hyperactivity (lytic phase), followed by a mixed phase, and finally osteoblastic overactivity (sclerotic phase). The resulting bone is structurally disorganized, woven bone that is mechanically weak and prone to deformity. This high-turnover state leads to increased vascularity and potential high-output heart failure.
Clinical Manifestations
Most patients are asymptomatic and diagnosed incidentally. Symptomatic patients present with bone pain, bone deformity (e.g., bowing of the tibia), or chalk-stick fractures. Hearing loss is a common complication of skull involvement. High-output heart failure may occur in extensive disease due to increased vascularity.
Diagnosis
The gold standard for diagnosis is plain radiographs showing lytic lesions or cortical thickening. Laboratory findings reveal an isolated, significantly elevated alkaline phosphatase with normal calcium and phosphate levels. A bone scan is the most sensitive test to determine the extent of skeletal involvement.
Treatment
Bisphosphonates (e.g., alendronate, risedronate) are the first-line therapy to suppress osteoclast activity. Esophagitis is a major risk, requiring patients to remain upright for 30 minutes post-dose. Osteonecrosis of the jaw is a rare but serious long-term complication. Calcitonin is a second-line alternative for patients who cannot tolerate bisphosphonates.
Prognosis
The most feared complication is the development of osteosarcoma, which should be suspected if there is a sudden increase in pain or a new lytic lesion. Patients require periodic monitoring of alkaline phosphatase levels to assess disease activity and response to therapy.
Differential Diagnosis
Metastatic bone disease: usually presents with multiple lesions and a known primary malignancy
Primary hyperparathyroidism: characterized by elevated calcium and PTH levels
Osteomalacia: associated with low vitamin D and low/normal calcium
Multiple myeloma: presents with lytic lesions and monoclonal protein spikes
Fibrous dysplasia: typically presents in younger patients with ground-glass appearance on imaging